China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images
Coronavirus: China approves first local neutralising antibody cocktail for high-risk patients
- Brii Biosciences says its therapy shows an 80 per cent reduction in hospital admissions and death in a global phase 3 trial
- HKU molecular virologist sees the therapy as an additional treatment option for China, but says it cannot replace the key role of vaccines
China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images
